RecruitingDrug trialStudy of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic CarcinomaThe goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)